US CDMO Expansion And Specialty Focus Will Strengthen Position

Published
20 Jul 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
NT$847.46
8.2% undervalued intrinsic discount
15 Aug
NT$778.00
Loading
1Y
27.0%
7D
8.7%

Author's Valuation

NT$847.5

8.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Aug 25
Fair value Decreased 15%

Bora Pharmaceuticals’ consensus price target has been notably reduced, likely reflecting a slight decline in its future P/E ratio while profit margins remain stable, resulting in a revised fair value of NT$813.95. What's in the News Completed share buyback of 36,000 shares (0.26%) for TWD 23.71 million.